UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000036588
Receipt number R000041612
Scientific Title Clinical trial of YAG laser vitreolysis for Weiss ring after posterior vitreous detachment
Date of disclosure of the study information 2019/04/24
Last modified on 2020/05/05 18:22:19

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Clinical trial of YAG laser vitreolysis for floater caused by Weiss ring

Acronym

Clinical trial of YAG laser vitreolysis for floater caused by Weiss ring

Scientific Title

Clinical trial of YAG laser vitreolysis for Weiss ring after posterior vitreous detachment

Scientific Title:Acronym

Clinical trial of YAG laser vitreolysis for Weiss ring after posterior vitreous detachment

Region

Japan


Condition

Condition

floater caused by Weiss ring

Classification by specialty

Ophthalmology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

A multi-center randomized, single-blind, controlled trial to evaluate safety and efficacy of the YAG laser vitreolysis for Weiss ring after posterior vitreous detachment.by comparing treated group with the sham YAG laser (placebo) treated group.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Pragmatic

Developmental phase

Phase IV


Assessment

Primary outcomes

Subjective change measured by visual questionnaire

Key secondary outcomes

a) visual acuity
b) ultrasound B scan
c) optical coherence tomography; OCT
d) fundus photo image
e) slit lamp examination, indirect ophthalmoscope,intra ocular pressure
f) National Eye Institute Visual Functioning Questionnaire 25(VFQ-25)


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Single blind -participants are blinded

Control

Placebo

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Device,equipment Maneuver

Interventions/Control_1

YAG laservitreolysis

Interventions/Control_2

sham YAG laser

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1) at least 6 month of symptom associated with floaters
2) posterior vitreous detachment confirmed by clinical examination, OCT and ultrasound B scan
3) more than 4 on the score of visual disturbance due to floaters (0 = no symptom, 10 = intolerable)
4) Weiss ring more than 3 mm away from the retina and 5 mm away from the lens not applicable if pseudophakic patients) by B scan
5) able to take position for YAG laser
6) understands the risk of YAG laser resulting in retinal detachment, intraocular hemorrhage, retinal injury, cataract formation, optic disc injury, inflammation, and other events causing visual disturbance
7) willing to cooperate to the study protocol
8) only one eye for the study even if the patient had symptom in both eye
9) willing to sign informed consent

Key exclusion criteria

1) fellow eye with best corrected visual acuity bellow 0.4(20/50)
2) history of retinal break, retinal detachment, uveitis in the study eye
3) history of diabetic retinopathy, macular edema, retinal vein occlusion, or aphakia in the study eye
4) ongoing treatment of glaucoma or ocular hypertension by more than 2 kinds of glaucoma topical medication, history of glaucoma surgery in the study eye

Target sample size

75


Research contact person

Name of lead principal investigator

1st name Shigeru
Middle name
Last name Kinoshita

Organization

ShijoKarasuma-Ganka Komuro Clinic

Division name

Department of Ophthalmology

Zip code

604-8152

Address

4th Floor High-medic Court, 652 Tearaimizu-cho, Nakagyo-ku, Kyoto

TEL

075-708-8004

Email

shigeruk@koto.kpu-m.ac.jp


Public contact

Name of contact person

1st name Keiko
Middle name
Last name Misawa

Organization

The Study Group for Laser Vitreolysis

Division name

Secretariat

Zip code

104-0053

Address

3rd floor Harumi Park Building, 3-2-22 Harumi, Chuo-ku, Tokyo

TEL

090-6009-7912

Homepage URL

https://laser-vitreolysis.net

Email

study1@laser-vitreolysis.net


Sponsor or person

Institute

The Study Group for Laser Vitreolysis

Institute

Department

Personal name



Funding Source

Organization

The Study Group for Laser Vitreolysis

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Kyoto Review Board

Address

5th Floor, 15th Hase Building, 688 Takanna-cho, Nakagyo-ku, Kyoto

Tel

075-746-6835

Email

Keigo.ishikawa1027@gmail.com


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2019 Year 04 Month 24 Day


Related information

URL releasing protocol

https://laser-vitreolysis.net

Publication of results

Unpublished


Result

URL related to results and publications

https://laser-vitreolysis.net

Number of participants that the trial has enrolled

49

Results

In the YAG laser vitreolysis group, the 10-point visual disturbance score improved by 2.5 vs 0.4 in the sham group (difference, -2.1; 95% CI, -3.3 to -0.9; P < .001). The YAG laser vitreolysis group reported greater symptomatic improvement (54%) than controls (18%) (difference, 36.1; 95% CI, 20.0-52.3; P < .001).

Results date posted

2020 Year 05 Month 05 Day

Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics

The mean (SD) age of participants was 60.2 (10.0) years in the YAG laser vitreolysis treatment group (age range, 41-79 years; median age 60 years) and 60.5 (11.2) years in the sham group (age range, 40-88 years; median age, 60 years).

Participant flow

49 patients (49 eyes; 18 men and 31 women) with symptomatic Weiss rings were enrolled and followed for 6 months.

Adverse events

In the YAG laser vitreolysis group, no adverse events, including lens or retinal injury, were observed. In the sham group, one participant had pneumonia during the study period and admitted to the hospital.

Outcome measures

Primary outcome at 6 months were subjective changes measured using a 10-point visual disturbance score. Secondary outcomes included improvement of visual disturbance expressed by percentage and a 5-level qualitative scale compared to baseline, postoperative floater symptoms (subjective symptoms and objective symptoms evaluated by funduscopy), and National Eye Institute Visual Functioning Questionnaire 25 (NEI VFQ-25).

Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

No longer recruiting

Date of protocol fixation

2016 Year 11 Month 28 Day

Date of IRB

2017 Year 01 Month 04 Day

Anticipated trial start date

2017 Year 03 Month 01 Day

Last follow-up date

2018 Year 06 Month 30 Day

Date of closure to data entry

2018 Year 07 Month 31 Day

Date trial data considered complete

2018 Year 09 Month 30 Day

Date analysis concluded

2018 Year 10 Month 31 Day


Other

Other related information



Management information

Registered date

2019 Year 04 Month 24 Day

Last modified on

2020 Year 05 Month 05 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000041612


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name